Leveraging the holistic benefits of biosimilars in Europe – part 2: how payers can safeguard the future of a healthy biosimilar market environment
Expert Review of Pharmacoeconomics & Outcomes Research · 2024
DOI: 10.1080/14737167.2024.2310684 ↗Kurz gefasst
Fachartikel in der Zeitschrift Expert Review of Pharmacoeconomics & Outcomes Research, 2024. Verfasst von Jorge Mestre-Ferrandiz und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Economics, Universidad Carlos III, Madrid, Spain. Hauptthemen laut MEDLINE: Biosimilar Pharmaceuticals. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Pfizer.
Abstract (Originalsprache)
INTRODUCTION: Biosimilars have improved access to biologic medicines; however, historical thinking may jeopardize the viability of future markets. AREAS COVERED: An expert panel of eight diverse European stakeholders provided insights about rethinking biosimilars and cost-savings, reducing patient access inequalities, increasing inter-market equity, and improving education. The insights reported here (Part 2) follow a study that provides perspectives on leveraging the holistic benefits of biosimilars for market sustainability based on independent survey results and telephone interviews of stakeholders from diverse biosimilar markets (Part 1). Directional recommendations are provided for payers. EXPERT OPINION: The panel's market maturity framework for biosimilars has three stages: 'Invest,' 'Expand' and 'Harvest.' Across market stages, re-thinking the benefits of biosimilars beyond cost-savings, considering earlier or expanded access/new indications, product innovations, and re-investment of biosimilar-generated cost-savings should be communicated to stakeholders to promote further engagement. During 'Expand' and 'Harvest' stages, development of efficient, forward-looking procurement systems and mechanisms that drive uptake and stabilize competition between manufacturers are key. Future biosimilars will target various therapy areas beyond those targeted by existing biosimilars. To ensure a healthy, accessible future market, stakeholders must align their objectives, communicate, collaborate, and coordinate via education, incentivization, and procurement, to maximize the totality of benefits.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Economics, Universidad Carlos III, Madrid, Spain.
- Department of Pharmacoeconomics, Institute of Mother and Child, Warsaw, Poland.
- Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria.
- Comparative Outcomes Group, Bristol, UK.
- Cancer Center, Clinique de Genolier, Vaud, Switzerland.
- Gastroenterology and Endoscopy, IRCCS Ospedale San Raffaele and University Vita-Salute San Raffaele, Milan, Italy.
Förderung
- Pfizer
Zitieren
APA
Mestre-Ferrandiz, J., Czech, M., Smolen, J. S., Cornes, P., Aapro, M. S., Danese, S., Deitch, S., Tyldsley, H., Foster, W., Shah, P., Latymer, M., & Vulto, A. G. (2024). Leveraging the holistic benefits of biosimilars in Europe – part 2: how payers can safeguard the future of a healthy biosimilar market environment. Expert Review of Pharmacoeconomics & Outcomes Research. https://doi.org/10.1080/14737167.2024.2310684
Vancouver
Mestre-Ferrandiz J, Czech M, Smolen JS, Cornes P, Aapro MS, Danese S, et al. Leveraging the holistic benefits of biosimilars in Europe – part 2: how payers can safeguard the future of a healthy biosimilar market environment. Expert Review of Pharmacoeconomics & Outcomes Research. 2024. doi:10.1080/14737167.2024.2310684
BibTeX
@article{MestreFerrandiz2024,
author = {Mestre-Ferrandiz, Jorge and Czech, Marcin and Smolen, Josef S and Cornes, Paul and Aapro, Matti S and Danese, Silvio and Deitch, Stephen and Tyldsley, Hannah and Foster, Will and Shah, Pooja and Latymer, Mark and Vulto, Arnold G},
title = {Leveraging the holistic benefits of biosimilars in Europe – part 2: how payers can safeguard the future of a healthy biosimilar market environment},
journal = {Expert Review of Pharmacoeconomics & Outcomes Research},
year = {2024},
doi = {10.1080/14737167.2024.2310684}
}
EUVIMED